Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Newly diagnosed acute lymphoblastic leukemia/lymphoma

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (3 if it is directly
             disease related and is expected to get better if the acute lymphoblastic
             leukemia/lymphoma [ALL] is under control)

          -  Left ventricular ejection fraction (LVEF) > 40%

          -  Total bilirubin =< 3 mg/dL

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.5 x
             upper limit of normal

          -  Creatinine clearance (CrCl) >= 45 mL/minute within 7 days prior to enrollment either
             measured or calculated using a standard formula (eg, Cockcroft and Gault); in cases
             that creatinine clearance cannot be measured accurately, 24 hour urine can be used

          -  Disease free of other malignancies beside the ALL at the time of the study

          -  Male subjects must agree to practice contraception

          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 50 mIU/mL within 24 hours prior to the initiation
             of the study and they must agree to ongoing pregnancy testing and to practice
             contraception

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form

          -  Pregnant or breast feeding females

          -  Active congestive heart failure (New York Heart Association [NYHA] class III to IV),
             symptomatic ischemia, or conduction abnormalities uncontrolled by conventional
             intervention

          -  Unstable angina or myocardial infarction within 6 months prior to enrollment, NYHA
             class III or IV heart failure, uncontrolled angina, history of severe coronary artery
             disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or
             electrocardiographic evidence of acute ischemia or grade 3 conduction system
             abnormalities unless subject has a pacemaker

          -  Uncontrolled hypertension, uncontrolled pulmonary hypertension or uncontrolled
             diabetes within 14 days prior to enrollment

          -  Subjects with pleural effusions requiring thoracentesis or ascites requiring
             paracentesis within 14 days prior to enrollment

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study

          -  Use of any other experimental drug or therapy within 14 days of baseline

          -  Known history of allergy to Captisol®

          -  Known sero-positive for active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are
             sero-positive because of hepatitis B virus vaccine are eligible

          -  Breakpoint cluster region-Abelson positive (BCR-ABL +) patients will be excluded from
             the study